All-Bran Immune Care Sales Begin!

●Kirin Holdings and Kellogg Japan have announced the release of a new addition to the Kellogg's All Bran lineup, All-Bran Immune Care, a “double health claim” functional food containing Kirin Group's proprietary ingredient L. lactis strain Plasma (postbiotic) and wheat bran derived fermented fiber arabinoxylan
●All-Bran Immune Care will go on sale on Amazon.co.jp on June 26
●This is the first "meal" type product as a functional food containing L. lactis strain Plasma (rather than a snack or side dish)

TOKYO, Monday May 29, 2023 - Kirin Holdings Company, Limited (Kirin Holdings) and KELLOGG(JAPAN)G.K. have announced the release of a new addition to the Kellogg's All Bran lineup, All-Bran Immune Care, a “double health claim” functional food containing Kirin Holdings’ proprietary ingredient L. lactis strain Plasma (postbiotic) and wheat bran derived fermented fiber arabinoxylan, a fermentable dietary fiber derived from wheat bran. All-Bran Immune Care will go on sale on the Amazon.co.jp site on June 26. This is the first "meal" type product as a functional food containing L. lactis strain Plasma (as opposed to a snack or side dish).

Amid growing awareness of the need to manage one's health, a FiNC Technologies, Inc. survey found that about half of those who engage in intestinal care are highly concerned about their immune system*1 . To address this health issue, Kirin Holdings and Kellogg's have jointly developed All-Bran Immune Care, which contains L. lactis strain Plasma in the All Bran series, which is rich in dietary fiber and supported by consumers worldwide as a product suitable for improving the intestinal environment. This product is a functional food with a “double health” claim that combines L. lactis strain Plasma, which helps maintain immune function in healthy people, and arabinoxylan, a fermentable dietary fiber derived from wheat bran that improves the intestinal environment and regulates stomach conditions. By adding the function of L. lactis strain Plasma to All Bran, which can be enjoyed as a daily meal, Kirin Holdings aim to make “immune care” an even more routine and habitual activity.
*1 According to FiNC Technologies, Inc., n=3,684, survey date: August 2021

Reported Indication

This product contains arabinoxylan derived from wheat bran and L. lactis strain Plasma. Wheat bran-derived arabinoxylan is a fermentable dietary fiber that has been reported to improve the intestinal environment by increasing butyric acid bacteria in the intestines, known as good bacteria, and increasing butyric acid. In addition, wheat bran-derived arabinoxylan derived from wheat bran is also reported to improve bowel movements by regulating the condition of the stomach. L. lactis strain Plasma is reported to work on pDC (plasmacytoid dendritic cells) and help maintain immune function in healthy people.

・Eating habits should be based on staple foods, main dishes, and side dishes, with a balance of meals.
・This product has not been approved by the government.
・This product is not intended to diagnose, treat, or prevent disease.

Reference

1．Product name	All-Bran Immune Care
2．Container/Size	280g
3．Sales area	Pre-sale on Amazon.co.jp
4．Release date	June 26, 2023
5．Price	Open price
6．Distributor	KELLOGG(JAPAN)G.K
7. Registration No.	H785

About Kirin Holdings

Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.
Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.
Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV* creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.
*Creating Shared Value. Combined added value for consumers as well as for society at large.

GALLERY